ClinicalTrials.gg
RecruitingNCT07463872Updated Mar 11, 2026

Management of Pancreatic Cystic Lesions Using Artificial Intelligence Based on EUS and Multimodal Data

An observational study in Pancreatic Cystic Lesion, Mucinous Cystadenoma of Pancreas and Intraductal Papillary Mucinous Neoplasm of Pancreas, sponsored by Huazhong University of Science and Technology. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Huazhong University of Science and Technology · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective is to construct a multimodal AI model (Cyst-AI) based on EUS images and clinical data such as imaging features(CT or MRI) and laboratory tests to assist endoscopists in the diagnosis of pancreatic cystic lesions(PCLs), mainly differentiating mucinous from non-mucinous lesions.

The secondary objective is to evaluate the model's effectiveness in risk stratification and clinical management for patients with PCLs.

Read the detailed description

With the development of medical imaging technology, the detection rate of pancreatic cystic lesions (PCLs) has been increasing notably. Although most cysts are benign, a considerable subset has the potential for malignant transformation. Clinical management is based on diagnosis and risk stratification. For PCLs,different diagnosis and risk stratification lead to entirely different clinical strategies and outcomes, which are closely related to the quality of life, economic burden, and psychological stress of patients. Endoscopic ultrasound (EUS) has played a crucial role in the further differential diagnosis of PCLs. Artificial intelligence (AI) has also shown great potential in clinical diagnosis and management. Thus, we plan to retrospectively collect patients' EUS imaging data, radiological and laboratory tests, and other clinical information to construct a model named Cyst-AI which integrates the function of diagnosis and clinical management, to assist in clinical decision-making.

02

Conditions studied

  • Pancreatic Cystic Lesion
  • Mucinous Cystadenoma of Pancreas
  • Intraductal Papillary Mucinous Neoplasm of Pancreas
  • Pseudocyst Pancreas
  • Serous Cystadenoma
  • Neuroendocrine Tumors, NET

Keywords

  • pancreatic cystic lesions
  • artificial intelligence
  • endoscopic ultrasound
  • multimodal
  • differentiation
  • risk stratification
  • clinical management
03

In context

Pancreatic Intraductal Neoplasms

32 studies on the registry are indexed under Pancreatic Intraductal Neoplasms; 21 are open to participants now.

This study's planned enrollment of 500 is below the median of 586 across 17 observational studies indexed under Pancreatic Intraductal Neoplasms.

Browse Pancreatic Intraductal Neoplasms studies →

Lead sponsor

Huazhong University of Science and Technology is the lead sponsor of 248 studies on the registry; 62 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The cohort will be selected from several hospitals in China, including Tongji Hospital, Tongji Medical College, HUST.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients whose EUS results indicates pancreatic cystic or cystoid lesions;
  • Mucinous lesions: including mucinous cystic neoplasm (MCN), intraductal papillary mucinous neoplasm (IPMN);
  • Non-mucinous lesions: including pancreatic pseudocyst, serous cystic neoplasm (SCN), cystic neuroendocrine tumor (cNET).

Exclusion criteria

Exclusion criteria:

  • Patients whose age is less than 18 years old;
  • Patients who have undergone pancreatic surgery before the EUS examination;
  • Patients who have received chemotherapy and radiotherapy for pancreatic tumors before the EUS examination;
  • Pathological results indicate that pancreatic lesions are lesions from other sites;
  • Patients whose EUS images or reports are missing;
  • EUS image quality does not meet the requirements for review, such as blurry imaging or containing artifacts, needles, measuring scales, or other additional annotations that are not part of the original EUS image;
  • Patients whose final diagnosis is unclear.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cyst-EUS

    Patients before 2026 with EUS pictures of pancreatic cystic lesions or cystoid-material lesions have been included in this cohort.

    Diagnostic Test: Cyst-AI model

Interventions

  • Diagnostic testCyst-AI model

    The multi-center collected data will be divided into a training set, a validation set, and a test set for developing and testing the cyst-AI model.

06

What researchers measure

Primary outcomes

  1. The performance of the diagnostic model in differentiating mucinous from non-mucinous PCLs

    The performance of the Cyst-AI diagnostic model will be evaluated using the area under the receiver operating characteristic curve (AUC-ROC), with sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) calculated from the model's predictions on the independent validation dataset. PCLs: pancreatic cystic lesions.

    Time frame: Within 3 months upon completion of the diagnostic model training.

  2. The risk stratification performance of the clinical management model for mucinous PCLs

    The performance of the Cyst-AI risk stratification model to correctly classify lesions into "low risk", "intermediate risk" and "high risk", will be evaluated using the area under the receiver operating characteristic curve (AUC-ROC), with sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) calculated from the model's predictions on the independent validation dataset. PCLs: pancreatic cystic lesions.

    Time frame: Within 3 months upon completion of the risk stratification model training.

Secondary outcomes

  1. The performance of the diagnostic model in differentiating specific types of PCLs

    The performance of the Cyst-AI diagnostic model will be evaluated using the area under the receiver operating characteristic curve (AUC-ROC), with sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) calculated from the model's predictions on the independent validation dataset. PCLs: pancreatic cystic lesions.

    Time frame: Within 3 months upon completion of the diagnostic model training.

  2. The clinical management performance of the clinical management model for mucinous PCLs

    The performance of the Cyst-AI clinical management model to provide accurate clinical recommendations, will be evaluated using the area under the receiver operating characteristic curve (AUC-ROC), with sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) calculated from the model's predictions on the independent validation dataset. PCLs: pancreatic cystic lesions.

    Time frame: Within 3 months upon completion of the clinical management model training.

  3. The performance of the model in assisting endoscopists of different levels in diagnosing and managing PCLs

    The performance of the Cyst-AI model in assisting endoscopists will be evaluated using the area under the receiver operating characteristic curve (AUC-ROC), with sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) calculated from the model's predictions on the independent validation dataset. PCLs: pancreatic cystic lesions.

    Time frame: Within 1 months upon completion of the human-machine confrontational crossover study

  4. The impact of the model on the decision-making process of endoscopists

    Questionnaire for endoscopists after assessment will be used to evaluate the degree of impact.

    Time frame: Within 1 months upon completion of the human-machine confrontational crossover study.

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Apr 2026, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Mar 11, 2026
StartActual
Jan 1, 2025
Primary completionEst.
Apr 2026
CompletionEst.
Jun 2026
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07463872
Responsible party
Bin Cheng (Professor, Huazhong University of Science and Technology) — Principal investigator
First posted
Mar 11, 2026
Start date
Jan 1, 2025
Primary completion
Apr 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Mar 11, 2026

Study contacts

Bin Cheng
Contact
b.cheng@tjh.tjmu.edu.cn
86-13986097542

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion